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Abstract: BACKGROUND It is hardly possible to define osteosarcoma (OS) patients at greatest risk
for non-response to chemotherapy, metastasis and short survival times. Our goal was the investigation
of local expression of insulin-like growth factor (IGF-1) with regard to survival time of OS patients
using a tissue microarray (TMA). MATERIALS AND METHODS Tumor tissue specimens from surgical
primary tumor resections were collected from patients with OS. A TMA was composed, sections were
stained with rabbit anti-IGF-1 and grading was performed. Statistics involved Kaplan-Meier curves and
the log-rank test. RESULTS We analyzed immunohistochemical expression of local IGF-1 on a TMA
based on surgical primary tumor resections of 67 OS patients. The mean clinical follow-up time was 98
months. Twenty-two (33%) OS patients stained negatively and 44 (66%) OS patients stained positively
for IGF-1. Significantly shorter survival was detected with expression of IGF-1 (p=0.007). The 5-year
survival rate for patients expressing IGF-1 was 63% compared to 92% in patients without expression of
IGF-1. Non-responders to chemotherapy and patients with metastasis, who also stained positively for
IGF-1 manifested a significantly (p=0.002 and p<0.0001, respectively) shorter survival. CONCLUSION
Expression of local IGF-1 in primary tumor tissue appears to significantly affect the aggressiveness of OS,
may predict survival time and, above all, may discriminate patients with non-response to chemotherapy
and metastasis. This represents the basis for successful patient selection with regard to the decision
process for or against chemotherapy and the choice of the most effective therapeutic drug. It may be
a more important marker of tumor progression and indicator of prognosis than serum IGF-1. Novel
tumor markers and therapeutic agents targeting the local IGF-1 pathway may increase the likelihood of
therapeutic success.
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Abstract. Background: It is hardly possible to define
osteosarcoma (OS) patients at greatest risk for non-response
to chemotherapy, metastasis and short survival times. Our
goal was the investigation of local expression of insulin-like
growth factor (IGF-1) with regard to survival time of OS
patients using a tissue microarray (TMA). Materials and
Methods: Tumor tissue specimens from surgical primary
tumor resections were collected from patients with OS. A
TMA was composed, sections were stained with rabbit anti-
IGF-1 and grading was performed. Statistics involved
Kaplan-Meier curves and the log-rank test. Results: We
analyzed immunohistochemical expression of local IGF-1 on
a TMA based on surgical primary tumor resections of 67 OS
patients. The mean clinical follow-up time was 98 months.
Twenty-two (33%) OS patients stained negatively and 44
(66%) OS patients stained positively for IGF-1. Significantly
shorter survival was detected with expression of IGF-1
(p=0.007). The 5-year survival rate for patients expressing
IGF-1 was 63% compared to 92% in patients without
expression of IGF-1. Non-responders to chemotherapy and
patients with metastasis, who also stained positively for IGF-
1 manifested a significantly (p=0.002 and p<0.0001,
respectively) shorter survival. Conclusion: Expression of
local IGF-1 in primary tumor tissue appears to significantly
affect the aggressiveness of OS, may predict survival time
and, above all, may discriminate patients with non-response
to chemotherapy and metastasis. This represents the basis for
successful patient selection with regard to the decision
process for or against chemotherapy and the choice of the
most effective therapeutic drug. It may be a more important
marker of tumor progression and indicator of prognosis than
serum IGF-1. Novel tumor markers and therapeutic agents
targeting the local IGF-1 pathway may increase the
likelihood of therapeutic success.
With an incidence rate approximately three to five cases per
million population per year, osteosarcoma (OS) is the most
common primary malignant bone tumor (1, 2). Therapeutic
approaches combine neoadjuvant chemotherapy, limb-
sparing surgery and histological tumor grading (3-5). Five-
year survival rates usually do not exceed 75% (6, 7) and are
even less favorable (20%) with non-response to
chemotherapy and metastasis (8-10). Shorter survival times
are also found in older patients, axial tumors and non-
responders to chemotherapy (9, 10). 
To facilitate the understanding of the course of disease and
treatment of OS, it is crucial to detect biomarkers that predict
patient survival (11). This is particularly true for rare
cancers, such as OS (12-14). Only a few biomarkers (5, 15-
19) for OS have been discussed. Cyr61 (5), ezrin (15), p53
(16) and tumor progression genes (17) have been associated
with worse courses of disease, whereas HER2 (18, 20) has
yielded equivocal results as a prognostic factor. However,
they are important in order to define patient outcomes, with
regard to the decision process for or against chemotherapy
and the choice of drug, patient education and because
survivors of sarcomas have one of the lowest health quality
of life scores (21, 22). 
Local expression of another biomarker, insulin-like growth
factor-1 (IGF-1) has been linked to OS as well. Increased
expression of IGF-1 has been shown in OS and their
metastases (23, 24). But so far, local IGF-1 in primary tumor
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tissue has not been studied as an indicator of prognosis. IGF-
1 is a hormone synthesized in the liver and to a lesser extent
in autocrine/paracrine tissues. IGF-1 production is mainly
stimulated by growth hormones (25). More than 98% of IGF-
1 is bound to six serum proteins (26). There are four IGF-1
receptors (IGF-1R), which are tyrosine kinases (27). They
require one of three ligands, namely IGF-1, IGF-2 or insulin,
which bind with different affinities to their cognate and
noncognate receptors. Once binding occurs, the receptor
autophosphorylates tyrosine residues intracellularly (28).
This activates mitogen-activated protein kinases,
phosphoinositide 3-kinases and protein kinase C epsilon
(29). Cell growth and inhibition of apoptosis follows (30,
31). The IGF-1 signaling pathway (32) is also responsible for
osteogenesis (33), contributing to about 50% of bone cell
proliferation (34).
IGF-1 has been implicated in various cancers, such as
breast and prostate cancers (35-37) and congenital IGF-1
deficiency acts as a protecting factor for the development
of cancer (38). Interestingly, IGF-1 has been linked to OS,
because the highest levels of IGF-1 (and growth hormone)
and the peak incidence of OS coincide around adolescence
(23). Increased levels of IGF-1 and IGF-1R have been
detected in OS (20, 24, 39). They lead to tumor progression
(40) through autocrine signaling (24), angiogenesis (41),
decreased susceptibility to apoptosis by IGF-1R
overexpression (42) and metastasis (43). Increased mRNA
levels of IGF-1R are also associated with proliferative OS
cell line activity (44). Blockage of the IGF-1R, for example
with trastuzumab (20), inhibits tumor growth of several
human OS cell lines (32). Thus, IGF-1 (45) and IGF-1R
(46) have been subject to various therapeutic approaches
(47-49). In Ewing’s sarcoma, disruption of IGF-1R
signaling leads to inhibition of tumor growth and metastasis
(50) by suppressing cell migration and expression of MMP-
2 and MMP-9 (51). Several therapeutic approaches, such as
antibodies like OncoLar (39, 52), antisense technologies
(53) and dominant-negative mutants (54) have been
successfully used for reduction of tumor growth and
inhibition of apoptosis. Furthermore, inhibition of IGF-1R
resulted in chemosensitization to conventional cytotoxic
drugs, such as trastuzumab (20), doxorubicin (55),
vincristine (56) and actinomycin D (57). With a few
exceptions (40, 58), studies have been based on in vitro and
in vivo animal experiments (25, 39), Ewing sarcomas (50,
59) and indirect assessment through OS growth inhibition
by hypophysectomy (60). Furthermore, clinical
investigations have not found an association between serum
IGF-1 levels and patient outcomes (58, 61). So far, to the
best of our knowledge there are no studies describing the
local expression of IGF-1 in primary tumor tissues and its
association with patient demographics and survival time in
human patients (23, 24).
Currently, it is hardly possible to define OS patients at
greatest risk for non-response to chemotherapy, metastasis
and short survival times (19). Valuable tumor biomarkers for
OS and their association with patient demographics and
survival time remain barely known. Our goal was the
investigation of IGF-1 with regard to demographics and
survival time in OS patients using a TMA. A particular focus
was put on the question whether expression of IGF-1 may
identify patients with metastasis and non-response to
chemotherapy, which would represent the basis for
successful patient selection with regard to the decision
process for or against chemotherapy, and the choice of the
most effective therapeutic agent.
Materials and Methods
Patients’ demographics. Tumor tissue specimens from surgical
primary tumor resections were collected from bone tissue of 67
patients with OS between December 1987 and October 2005. By a
retrospective chart review, a database was established containing
information about patient demographics, such as response to
chemotherapy, metastasis and patient survival. Tumor tissue
specimens were grouped according to the histopathological
classification by the World Health Organization (WHO) (62).
Chemotherapy was administered according to the COSS protocol
(63). According to Salzer-Kuntschik et al. (64), patients were
responders to chemotherapy if less than 10% of vital tumor tissue was
present in the surgical resection specimen. This study was conducted
according to the regulations of the local ethics committee.
IGF-1 and TMA. After surgical resection of the tumor, biopsies were
taken from parts with histologically-confirmed non-necrotic tumor
tissues from 67 patients. A tissue microarray (TMA) (12, 19, 65-73)
was set up in order to maximize the use of tumor tissue from
biopsies for as many immunohistochemical tests as possible
requiring only small amounts of tissue. Using a hollow needle with
a diameter of 0.6 mm of a semi-automatic punch machine, between
two and six tissue cores were removed from these biopsies (16, 74).
Tissue cores were implanted in a recipient paraffin block in an array
pattern using a computer-operated electromotor resulting in 174
spots for surgical resections. There were a total of 404 spots (Figure
1A) because several patients also provided tissue specimens from
presurgical biopsies, recurrences and metastases. The paraffin block
was cut into several sections of 2 μm in order to be available for
immunohistochemical staining. A section of the TMA was
transferred to an adhesive-coated slide system (Instrumedics,
Hackensack, NJ, USA), de-paraffinized and processed with a bond
automated staining system (Ventana Medical Systems, Tucson, AZ,
USA). After antigen retrieval in an EDTA containing buffer (Bond
Epitope Retrieval Solution 2) (Vision BioSystems, Wetzlar,
Germany) for 30 min, the section was stained with a rabbit anti-
IGF-1 antibody (dilution 1:50) (LabVision/Neomarkers, Fremont,
CA, USA) and counterstained with hematoxylin. Visualization of
primary antibody reactions, which resulted in a brown product, was
undertaken by iVIEW DAB Kit (Ventana Medical Systems). Three
formalin-fixed paraffin-embedded control sections with known
staining patterns were used for quality control. Grading was
undertaken independently by a physician, who had been trained by
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a pathologist and a student, using the MATLAB code based on color
deconvolution (75, 76). In both cases, grading was carried out in a
blinded fashion. In the end, more than 95% of the samples were
graded similarly. For the remaining samples a consensus was found.
A grading scale of 1, 2 and 3 was used. Grade 1 indicated negative
(Figure 1B) staining with <10% of stained cells with no or weak
staining intensity, whereas grades 2 (Figure 1C) and 3 (Figure 1D)
indicated positive staining with ≥10% stained cells with weak or
strong staining intensity, respectively (66). Grade 3 was reserved for
staining of all cells with maximum intensity. For final evaluation
purposes, we grouped negative, that is grade 1 staining, against
positive, that is grade 2 and 3 staining. 
Statistical analysis. Kaplan-Meier curves were used to calculate
overall patient survival, which was defined as the time from
diagnosis until death or last patient contact. Means and confidence
intervals were stated. The log-rank (Mantel-Cox) test assessed the
statistical difference between groups. Significant statistical
difference was assumed if p<0.05. We used the GraphPad Prism
5.01 software (GraphPad Software, La Jolla, CA, USA) and SPSS
statistics v21.0 (IBM Corp., Armonk, NY, USA). 
Results
Patients’ demographics. We analyzed clinical parameters of
67 OS patients and immunohistochemical expression of IGF-
1 on corresponding tumor tissue. Follow-up data were
available for every (100%) patient and the mean clinical
follow up time was 98 (range, 7 to 213) months. The overall
5-year survival rate was 73%. Our study included 24 (36%)
female and 43 (64%) male patients. At the time of diagnosis,
the mean age was 22 (range=2-66) years. Our study included
23 (34%) non-responders to chemotherapy and 30 (45%)
responders. Chemotherapy response remained unknown in
14 (21%) patients. Nineteen (28%) patients developed
metastases during follow-up, whereby 5 (7%) patients
already presented with metastases at diagnosis. Twenty
(30%) patients had metastases in the lung and 3 patients
(4%) displayed metastases in the lung and the bone. One
patient (1%) presented with metastasis at an unknown site.
Survival time and IGF-1 in a TMA. Twenty-two (33%) OS
patients stained negatively and 44 (66%) OS patients stained
positively for IGF-1 on the TMA. One (1%) OS patient
could not be graded because spots did not contain sufficient
material of tumor tissue. The Kaplan-Meier survival analysis
showed shorter survival times for patients with
immunohistochemically-detectable expression of IGF-1 in
tumor tissues (Figure 2, Table I). Immunohistochemically-
detectable expression of IGF-1 was indicative for shorter
mean survival time of 132±14 months. In contrast, no
expression of IGF-1 led to longer mean survival time of
198±9 months. When comparing these groups with a log-
rank (Mantel-Cox) test, statistical significance (p=0.007) was
reached for these two groups. The five-year survival rate of
patients expressing IGF-1 was 63% compared to 92% of
patients without expression of IGF-1.
Non-responders to chemotherapy who stained positively for
IGF-1 manifested a significantly (p=0.002) shorter survival
time of 85±16 months than responders to chemotherapy who
stained negatively, whose mean survival time was
195±13months (Figure 3A, Table II). The 5-year survival rate
for non-responders with IGF-1 expression was 50% compared
to 92% for responders without IGF-1 expression.
Interestingly, the shortest survival time of 50±10 months was
found in patients with metastasis and immunohistochemical
expression of IGF-1 (Figure 3B, Table III). This was
significantly (p<0.0001) shorter than the survival time of
patients without metastasis and no immunohistochemical
expression of IGF-1. No survival times were computed for
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Table I. Patient (number of patients=n) survival (mean and standard
error in months=m) and p-values (log-rank test) are shown for IGF-1.
Positive Negative p-Value
IGF-1 n=44 n=22 0.007
132±14 m 198±9 m
63% 92%
Table II. Patient (number of patients=n) survival (mean and standard
error in months=m) in patients with OS with regard to non-response
and response to neoadjuvant chemotherapy as well as expression of
IGF-1. 
Non-responders Responders p-Value
Positive Negative Positive Negative
IGF-1 n=19 n=4 n=16 n=13 0.002
85±16 m * 174±18 m 195±13 m
50%100% 88% 92%
*No survival times were computed because all patients remained alive
and were censored.
Table III. Patient (number of patients=n) survival (mean and standard
error in months=m) in patients with OS with and without metastasis as
well as expression of IGF-1. 
Metastasis No metastasis p-Value
Positive Negative Positive Negative
IGF-1 n=3 n=4 n=24 n=18 <0.0001
50±10 m 125±37 m 183±13 m *
26% 75% 92% 100%
*No survival times were computed because all patients remained alive
and were censored.
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Figure 1. TMA slide with IGF-1 immunostaining. Control group of normal bone tissue on three vertical spots on the left and biopsies of OS patients
on the remaining 404 spots (A). Negatively-graded spot (grade 1=B) showing mainly blue staining. Positively-graded spots (grade 2=C and grade
3=D) showing mainly brown staining.
patients without metastasis and no expression of IGF-1 because
all patients remained alive and were censored. The 5-year
survival rate for patients with metastasis expressing IGF-1 was
26% compared to 100% in patients without metastasis and no
expression of IGF-1.
Discussion
Our study suggests that local IGF-1 expression in surgical
primary tumor resection tissue specimens in patients with OS
goes along with more aggressive tumor types associate with
an increased number of metastasis, non-response to
chemotherapy and worse survival time. 
OS is the most common primary malignant bone tumor
(1), but relatively rare in comparison to other cancers (35,
36). Survivors of sarcomas have one of the lowest health
quality of life scores (22). Particularly, valuable tumor
biomarkers for OS and their association with patient
demographics and survival time remain barely studied
because patient data are limited (19). However, they are
especially important in order to define patient outcomes at
the time of diagnosis, treatment decisions and ultimately
patient education (21). The role of IGF-1 in OS has been
investigated in several studies (20, 23, 24, 58, 61), but to the
best of our knowledge no clinical information is available on
the expression of local IGF-1 of the primary tumor as an
indicator of prognosis (23, 24). Burrow et al. (24) examined
48 patients with osteosarcoma with regard to their IGF-1
expression in primary tumors and metastasis using reverse
transcriptase-polymerase chain reaction (RT-PCR). Twenty-
seven (61%) of 44 tumors expressed levels of IGF-1 greater
than or equal to the positive control group. Higher levels of
IGF-1 were not correlated with metastasis. However, they did
not correlate their findings with clinical patient data. Another
study by Scotlandi et al. (20) investigated the IGF-1R
functions in two Ewing sarcoma and two OS cell lines. They
studied the in vitro efficacy of trastuzumab in association
with anti-IGF-1R treatment (neutralizing anti-IGF-1R αIR3
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Figure 2. Patient survival in patients with OS expressing IGF-1.
Figure 3. Patient survival in patients with OS in non-responders and
responders to chemotherapy and IGF-1 expression (A) as well as with
and without metastasis and expression of IGF-1 (B). 
monoclonal antibody) because IGF-1R plays a role in
resistance to trastuzumab (20, 37). Their results showed that
αIR3 enhanced the trastuzumab-induced growth inhibition in
these cell lines. This was confirmed by an increased
susceptibility to trastuzumab in Ewing sarcoma cell lines,
TC-71 derived clones with impaired IGF-1R functions (20).
Above all, IGF-1 discriminates patients with metastasis
and non-response to chemotherapy. This represents the basis
for successful patient selection with regard to the decision
process for or against chemotherapy and the choice of the
most effective therapeutic drug. In the future, it may be
advisable to separate patients according to the expression of
IGF-1 and possibly treat only those who are most likely to
benefit from chemotherapy. Thus, patients who are not likely
to benefit from chemotherapy may not have to undergo
unnecessary chemotherapy that is accompanied by many
adverse effects.
Our study adds important information to the current
literature, because we point out that local IGF-1 expression
in primary tumor tissue may be a more important indicator
of tumor progression and of prognosis than serum IGF-1.
Circulating concentrations of IGF-1 were previously
described as non-predictive of clinical characteristics of
OS patients in a study by Rodriguez-Galindo et al. (61).
They investigated serum IGF-1 in 37 patients with OS by
ELISA. IGF-1 levels were not significantly associated with
response to chemotherapy (p=0.95), metastasis (p=0.12)
and survival time (p=0.52). Likewise, Borinstein et al. (58)
recently investigated serum levels of IGF-1 in 142 OS
patients and did not find an association with overall
survival. In a murine OS model, Hong et al. (23) did not
find evidence that serum IGF-1 played a role in local
tumor progression or metastasis. They injected K7M2
murine OS cells into genetically- engineered, liver-specific
IGF-1-deficient mice with 75% reduction in IGF-1 levels
while maintaining IGF-1 in the tumor environment. On the
other hand, there are reports about increased IGF-1 levels
leading to tumor growth (40) through autocrine signaling
(24), angiogenesis (41), decreased susceptibility to
apoptosis by IGF-1R overexpression (42) and metastasis
(43). Furthermore, Kolb et al. (39) reported inhibition of
tumor growth by anti-IGF-1R antibodies in xenografts in
vivo. Other pre-clinical data suggest efficacy of IGF-1R
antagonists (47) and these results were investigated in a
recent phase-2 study by Weigel et al. (48). They studied
the efficacy, pharmacodynamics and toxicities of single-
agent cixutumumab, which is a human IgG1/λ monoclonal
antibody against IGF-1R leading to inhibition of the IGF
pathway (49) in solid tumors including OS. Administration
of cixutumumab was tolerated well and led to increased
serum levels of IGF-1, confirming IGF-1 as an important
biomarker in OSs. In other words, our study points-out that
local IGF-1 expression in primary tumor tissue may be
much more important in tumor progression and as an
indicator of prognosis than serum IGF-1. In the future,
novel tumor markers for the IGF-1 pathway that target
local IGF-1 may increase the likelihood of therapeutic
success. 
To date, there are only a few OS TMAs in the commonly
cited in the English literature (12, 19, 67-73, 77). Patient
numbers are rather small, clinical information is limited and
tissue specimens usually derive from presurgical biopsies.
As a possible limitation, our study exclusively investigated
primary tumor tissue resections after chemotherapy instead
of biopsies before chemotherapy. Nonetheless, an additional
predictor of survival, aside from tumor necrosis, is very
important for clinicians and patients alike; no matter
whether this particular discriminator stems from the pre- or
post-chemotherapeutic phase. Furthermore, decisions on
adjuvant chemotherapy are not only based on biopsies, but
also on tumor necrosis rate in primary tumor tissue
resections. Therefore, IGF-1 in primary tumor tissue
resections provides an additional discriminator for patients
at an increased risk for shorter survival time, which may
arise from non-response to chemotherapy or metastasis.
Furthermore, immunohistochemistry of a TMA has limited
power in terms of antigen quantification. Nonetheless, the
advantage of a TMA is the evaluation of the local
expression of different tumor biomarkers in a large sample
number under the same conditions (65). It is understood that
the leading value of this study lies in its novelty report of
worse prognosis of osteosarcoma patients expressing local
IGF-1 in primary tumor tissue on a TMA by combining
clinical patient data with local tumor biomarker expression
in an immunohistochemical test method.
Conclusion
Our study suggests that local IGF-1 expression in surgical
primary tumor resection tissue specimens of patients with OS
is associated with more aggressive tumor types and survival
time. Above all, IGF-1 discriminates patients with metastasis
and non-response to chemotherapy. This represents the basis
for successful patient selection with regard to the decision
process for or against chemotherapy and the choice of the
most effective therapeutic drug. Furthermore, we point-out
that local IGF-1 expression in primary tumor tissues may be
much more important in tumor progression and as an
indicator of prognosis than serum IGF-1. In the future, novel
tumor markers and therapeutic agents for the IGF-1 pathway
that target local IGF-1 may increase the likelihood of
therapeutic success. 
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